Q-Line Biotech Limited

CAPITALISATION STATEMENT

(â‚¹ in Lakhs)

<table><thead><tr><th rowspan="2">Particulars</th><th>Pre Issue</th><th rowspan="2">Post Issue*</th></tr><tr><th>As on 31st March, 2025</th></tr></thead><tbody><tr><td><strong>Borrowings</strong></td><td></td><td></td></tr><tr><td>Short Term Debt</td><td>5,546.09</td><td>-</td></tr><tr><td>Long Term Debt</td><td>10,948.89</td><td>-</td></tr><tr><td><strong>Total Debts</strong></td><td><strong>16,494.98</strong></td><td><strong>-</strong></td></tr><tr><td><strong>Shareholders' funds</strong></td><td></td><td></td></tr><tr><td>Equity share capital</td><td>157.50</td><td>*</td></tr><tr><td>Reserve and surplus</td><td>18,837.03</td><td>*</td></tr><tr><td><strong>Total shareholders' funds</strong></td><td><strong>18,994.53</strong></td><td><strong>*</strong></td></tr><tr><td><strong>Long Term Debt / Shareholders' funds</strong></td><td>0.58</td><td>*</td></tr><tr><td><strong>Total Debt / Shareholders' funds</strong></td><td>0.87</td><td>*</td></tr></tbody></table>

* The corresponding post issue figures are not determinable at this stage.

Notes:

1. Short term Debts represent which are expected to be paid/payable within 12 months and excludes instalment of term loans repayable within 12 months.

2. Long term Debts represent debts other than Short Term Debts as defined above but includes instalment of term loans repayable within 12 months grouped under other current liabilities.

3. The figures disclosed above are based on restated statement of Assets and Liabilities of the Company as at March 31, 2025.

256